Patents by Inventor Diego Gianolio
Diego Gianolio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250066497Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: July 29, 2024Publication date: February 27, 2025Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 12110338Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: August 17, 2021Date of Patent: October 8, 2024Assignee: Genzyme CorporationInventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Publication number: 20240182595Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: September 7, 2023Publication date: June 6, 2024Inventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
-
Patent number: 11807690Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: October 17, 2019Date of Patent: November 7, 2023Assignee: GENZYME CORPORATIONInventors: Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio
-
Publication number: 20220089763Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: August 17, 2021Publication date: March 24, 2022Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 11130816Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: January 3, 2019Date of Patent: September 28, 2021Assignee: GENZYME CORPORATIONInventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Publication number: 20200140564Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: October 17, 2019Publication date: May 7, 2020Inventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
-
Patent number: 10494439Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: June 5, 2017Date of Patent: December 3, 2019Assignee: GENZYME CORPORATIONInventors: Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio
-
Publication number: 20190233531Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: January 3, 2019Publication date: August 1, 2019Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 10214589Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: January 27, 2017Date of Patent: February 26, 2019Assignee: GENZYME CORPORATIONInventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Publication number: 20170369584Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: June 5, 2017Publication date: December 28, 2017Inventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
-
Publication number: 20170267774Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: January 27, 2017Publication date: September 21, 2017Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Patent number: 9701753Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: March 10, 2014Date of Patent: July 11, 2017Assignee: GENZYME CORPORATIONInventors: Clark Pan, Huawei Qiu, Pradeep Dhal, Bo Chen, Diego Gianolio
-
Patent number: 9580511Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: GrantFiled: March 10, 2014Date of Patent: February 28, 2017Assignee: GENZYME CORPORATIONInventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
-
Publication number: 20150079070Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: March 10, 2014Publication date: March 19, 2015Applicant: Genzyme CorporationInventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
-
Publication number: 20140294867Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: March 10, 2014Publication date: October 2, 2014Applicant: Genzyme CorporationInventors: Clark PAN, Qun ZHOU, James STEFANO, Pradeep DHAL, Bo CHEN, Diego GIANOLIO, Robert MILLER, Huawei QIU
-
Patent number: 7387836Abstract: There are disclosed novel uses of aziridine compounds. The aziridine compounds can be formed into films by plasma deposition on a wide variety of substrates. The films prevent biofouling, impart biocompatible or antithrombotic properties, and can immobilize therapeutic and pharmaceutical agents to provide a drug delivery system.Type: GrantFiled: April 17, 2003Date of Patent: June 17, 2008Assignee: Genzyme CorporationInventors: Diego A. Gianolio, Erika E. Johnston, Robert J. Miller
-
Publication number: 20050249953Abstract: There are disclosed novel uses of aziridine compounds. The aziridine compounds can be formed into films by plasma deposition on a wide variety of substrates. The films prevent biofouling, impart biocompatible or antithrombotic properties, and can immobilize therapeutic and pharmaceutical agents to provide a drug delivery system.Type: ApplicationFiled: April 17, 2003Publication date: November 10, 2005Inventors: Diego Gianolio, Erika Johnston, Robert Miller
-
Publication number: 20050222081Abstract: There is disclosed a cross-linked hyaluronate compound obtained by reacting a sodium hyaluronate compound with a polfunctional aziridine compound as a cross-linking agent. The polyfunctional aziridine compound was added to hyaluronan of various molecular weights in an equivalent ratio of HA/AZ of 1:1 to 1:10, preferably, 1:3 to 1:10, more preferably, 1:3 to 1:5; most preferably 1:4 to 1:5. The polymeric hydrogel compounds obtained are useful to prevent the formation of post-operative adhesions, designing tissue engineering applications, and the like.Type: ApplicationFiled: April 17, 2003Publication date: October 6, 2005Inventors: Diego Gianolio, Pericles Calias, Robert Miller